Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CCM NASDAQ:IMMP NASDAQ:OTIC NASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCMConcord Medical Services$6.07+18.0%$5.40$3.80▼$10.77$22.32M-1.041,512 shs16,814 shsIMMPPrima BioMed$1.61-4.7%$1.70$1.32▼$2.71$248.07M1.7180,282 shs127,779 shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/ASVRASavara$3.53-1.9%$3.00$1.89▼$4.70$622.21M0.561.64 million shs3.69 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCMConcord Medical Services+0.54%+2.85%+2.00%-4.72%+4.32%IMMPPrima BioMed+1.20%+1.81%-4.52%+5.62%-24.22%OTICOtonomy0.00%0.00%0.00%0.00%0.00%SVRASavara0.00%+0.28%+18.03%+74.76%-18.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCMConcord Medical Services$6.07+18.0%$5.40$3.80▼$10.77$22.32M-1.041,512 shs16,814 shsIMMPPrima BioMed$1.61-4.7%$1.70$1.32▼$2.71$248.07M1.7180,282 shs127,779 shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/ASVRASavara$3.53-1.9%$3.00$1.89▼$4.70$622.21M0.561.64 million shs3.69 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCMConcord Medical Services+0.54%+2.85%+2.00%-4.72%+4.32%IMMPPrima BioMed+1.20%+1.81%-4.52%+5.62%-24.22%OTICOtonomy0.00%0.00%0.00%0.00%0.00%SVRASavara0.00%+0.28%+18.03%+74.76%-18.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCMConcord Medical Services 0.00N/AN/AN/AIMMPPrima BioMed 3.00Buy$7.00334.78% UpsideOTICOtonomy 0.00N/AN/AN/ASVRASavara 2.83Moderate Buy$7.50112.46% UpsideCurrent Analyst Ratings BreakdownLatest CCM, SVRA, OTIC, and IMMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025SVRASavaraGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $11.009/8/2025SVRASavaraOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$6.00 ➝ $8.009/3/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $8.008/15/2025SVRASavaraOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$5.00 ➝ $6.008/15/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$2.00 ➝ $5.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCMConcord Medical Services$52.60M0.50N/AN/A$51.05 per share0.12IMMPPrima BioMed$6.69M35.33N/AN/A$0.63 per share2.56OTICOtonomy$130K4.48N/AN/A$0.97 per share0.01SVRASavaraN/AN/AN/AN/A$1.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCMConcord Medical Services-$42.23MN/A0.00∞N/AN/AN/AN/AN/AIMMPPrima BioMed-$39.78MN/A0.00N/AN/AN/AN/AN/AN/AOTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/ASVRASavara-$95.88M-$0.50N/AN/AN/AN/A-69.05%-54.84%11/11/2025 (Estimated)Latest CCM, SVRA, OTIC, and IMMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q1 2025SVRASavara-$0.12-$0.14-$0.02-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCMConcord Medical ServicesN/AN/AN/AN/AN/AIMMPPrima BioMedN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCMConcord Medical Services1.670.460.45IMMPPrima BioMedN/A11.69N/AOTICOtonomyN/A1.741.74SVRASavara0.2511.0811.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCMConcord Medical ServicesN/AIMMPPrima BioMed2.32%OTICOtonomy41.23%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipCCMConcord Medical Services46.50%IMMPPrima BioMed3.07%OTICOtonomy1.09%SVRASavara5.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCMConcord Medical Services9704.34 million2.32 millionNot OptionableIMMPPrima BioMed2,021146.79 million142.28 millionOptionableOTICOtonomy5168.53 million67.78 millionOptionableSVRASavara20172.84 million163.63 millionOptionableCCM, SVRA, OTIC, and IMMP HeadlinesRecent News About These CompaniesNovember 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SVRASeptember 19 at 4:47 PM | globenewswire.comROSEN, LEADING INVESTOR COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action- SVRASeptember 19 at 3:51 PM | cantechletter.comCDeadline Alert: Savara Inc. (SVRA) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud LawsuitSeptember 19 at 1:09 PM | globenewswire.comShareholders of Savara Inc. Should Contact Levi & Korsinsky Before November 7, 2025 to Discuss Your Rights - SVRASeptember 19 at 10:50 AM | theglobeandmail.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action- SVRASeptember 19 at 10:50 AM | cantechletter.comCSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SavaraSeptember 19 at 10:50 AM | cantechletter.comCInvestors who lost money on Savara Inc.(SVRA) should contact Levi & Korsinsky about pending Class Action - SVRASeptember 19 at 8:45 AM | prnewswire.comFaruqi & Faruqi Reminds Savara Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2025 - SVRASeptember 18 at 6:13 PM | prnewswire.comSavara Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights – SVRASeptember 18 at 4:44 PM | globenewswire.comPortnoy Law Firm Announces Class Action on Behalf of Savara, Inc. InvestorsSeptember 18 at 1:41 PM | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRASeptember 18 at 10:00 AM | prnewswire.comRecover Investment Losses: Levi & Korsinsky Files Class Action Against Savara Inc. (SVRA)September 18 at 4:32 AM | theglobeandmail.comRecover Investment Losses: Levi & Korsinsky Files Class Action Against Savara Inc. (SVRA)September 18 at 4:32 AM | theglobeandmail.comSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 18 at 4:32 AM | prnewswire.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SavaraSeptember 17 at 10:11 PM | globenewswire.comDeadline Alert: Savara Inc. (SVRA) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud LawsuitSeptember 17 at 1:52 PM | businesswire.comROSEN, A LEADING LAW FIRM, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Fraud Lawsuit – SVRASeptember 17 at 12:29 PM | globenewswire.comDid You Lose Money in SVRA? Shareholders Who Lost Money in SVRA Should Contact Robbins LLP for Information About the Savara Inc. Securities Class Action LawsuitSeptember 16 at 8:52 PM | prnewswire.comSVRA Investors have Opportunity to Lead Savara Inc. Securities Fraud LawsuitSeptember 16 at 8:01 PM | prnewswire.comRosen Law Firm Urges Savara Inc. (NASDAQ: SVRA) Stockholders with Large Losses to Contact the Firm for Information About Their RightsSeptember 16 at 6:00 PM | businesswire.comSavara (NASDAQ:SVRA) Stock Price Down 3.3% - Should You Sell?September 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Nextracker Stock Rockets as AI and Solar Tailwinds AlignBy Thomas Hughes | August 21, 2025The Uber Eats Partnership Fueling Serve Robotics' GrowthBy Jeffrey Neal Johnson | August 28, 2025AEHR Spikes 36% on Hyperscaler Order—Investors Should Take NoticeBy Leo Miller | August 27, 2025Reddit Hits Record Highs: Why Wall Street Is Taking NoticeBy Jeffrey Neal Johnson | September 15, 2025CCM, SVRA, OTIC, and IMMP Company DescriptionsConcord Medical Services NYSE:CCM$6.07 +0.93 (+18.02%) Closing price 03:55 PM EasternExtended Trading$5.96 -0.11 (-1.83%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.Prima BioMed NASDAQ:IMMP$1.61 -0.08 (-4.73%) Closing price 04:00 PM EasternExtended Trading$1.62 +0.01 (+0.93%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Otonomy NASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.Savara NASDAQ:SVRA$3.53 -0.07 (-1.94%) Closing price 04:00 PM EasternExtended Trading$3.49 -0.04 (-1.13%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Azure Leads While AI Excitement Fuels Microsoft Stock The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
